Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin in Advanced Systemic Mastocytosis
NCT00782067Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2008
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL) and systemic mastocytosis with associated hematological neoplasm (SM-AHN), sponsored by Novartis. Primary endpoint: Overall Response Rate at 6 months. Started Oct 2008; status: completed.
02
Drugs
midostaurin
03
Conditions
aggressive systemic mastocytosis (ASM)mast cell leukemia (MCL)systemic mastocytosis with associated hematological neoplasm (SM-AHN)
Beyond the preview
Go deeper on NCT00782067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782067.